| Literature DB >> 30120653 |
Peng Liu1, Yinjie Li1, Danyang Liu1, Xuefei Ji1, Tianyan Chi1, Lin Li2, Libo Zou3.
Abstract
Tolfenamic acid (TA), a nonsteroidal anti-inflammatory drug, shows neuroprotective effects and alleviates cognitive deficits in transgenic mouse models of Alzheimer's disease. However, whether TA can prevent the biochemical alterations induced by intraperitoneal injection of 3-nitropropionic acid (3-NP) in mice is still unknown. In this study, the striatal lesion area was measured by 2,3,5-triphenyltetrazolium chloride staining. Glutamate, SDH and ATP levels were tested using colorimetric assay kits. The neuroinflammatory cytokine levels were tested by ELISA kits. The expression of synaptic proteins and the subtypes of the NMDA receptor were tested by western blotting. TA was orally administered 10 days before 3-NP injection (pretreatment) or on the same day as 3-NP injection (co-treatment). TA pretreatment showed the strongest neuroprotective effects: pretreatment significantly attenuated the 3-NP-induced muscular weakness in the forelimb and alterations in glutamate level, mitochondrial function, and pro-inflammatory cytokine release in the brains of mice. These results suggest that TA has preventive and protective effects on 3-NP-induced neurotoxicity.Entities:
Keywords: 3-Nitropropionic acid; Huntington’s disease; Tolfenamic acid
Mesh:
Substances:
Year: 2018 PMID: 30120653 DOI: 10.1007/s11064-018-2615-7
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996